Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer

Pancreatic cancer (PDAC) is still lacking of reliable markers to monitor tumor response. CA 19-9 is the only biomarker approved, despite it has several limitations in sensitivity and specificity. Since mutations of KRAS occur in more than 90% of tumors, its detection in circulating free tumor DNA (c...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Rep
Main Authors: Del Re, Marzia, Vivaldi, Caterina, Rofi, Eleonora, Vasile, Enrico, Miccoli, Mario, Caparello, Chiara, d’Arienzo, Paolo Davide, Fornaro, Lorenzo, Falcone, Alfredo, Danesi, Romano
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5554237/
https://ncbi.nlm.nih.gov/pubmed/28801547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-08297-z
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki